Briefing: Drug company penalties for paying kickbacks to doctors failed to dent bottom lines, analysis finds

Penalized drugmakers paid only 2.2% of their U.S. revenue from the drugs in question.

The analysis covers a period of the past quarter century.

Kickback penalties have not significantly impacted the financial performance of these companies.